CAMP4 advances rare disease treatment for SYNGAP1 into human trials
- Posted on August 6, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Generating AI summary…
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 is preparing a Phase 1/2 trial of an experimental SYNGAP1 therapy, marking a major milestone for patients with the rare disease.
